CYTR Share Price

Open 0.82 Change Price %
High 0.82 1 Day -0.13 -16.05
Low 0.62 1 Week 0.07 11.48
Close 0.68 1 Month 0.26 61.90
Volume 14425503 1 Year -2.67 -79.70
52 Week High 3.44
52 Week Low 0.36
CYTR Important Levels
Resistance 2 0.87
Resistance 1 0.79
Pivot 0.71
Support 1 0.57
Support 2 0.49
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
SIRI 5.02 -1.76%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 37.43 1.35%
INTC 37.43 1.35%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
IFON 0.63 34.04%
WRES 0.09 28.57%
SMSI 1.13 28.41%
EXAS 30.14 26.64%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPHC 2.80 21.21%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
PGRX 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SNCR 13.29 -46.02%
DVOX 0.05 -44.44%
More..

CytRx Corporation (NASDAQ: CYTR)

CYTR Technical Analysis 2
As on 27th Apr 2017 CYTR Share Price closed @ 0.68 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.78 & Buy for SHORT-TERM with Stoploss of 0.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
CYTR Target for April
1st Target up-side 0.49
2nd Target up-side 0.52
3rd Target up-side 0.56
1st Target down-side 0.39
2nd Target down-side 0.36
3rd Target down-side 0.32
CYTR Other Details
Segment EQ
Market Capital 47314736.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cytrx.com
CYTR Address
CYTR
11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
Phone: 310-826-5648
Fax: 310-826-6139
CYTR Latest News
Interactive Technical Analysis Chart CytRx Corporation ( CYTR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on CytRx Corporation
CYTR Business Profile
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.